stockrowNeoGenomics, Inc. (NEO) vs Personalis, Inc. (PSNL)
- NeoGenomics, Inc. NEO 16.55 −3.50%
- Personalis, Inc. PSNL 15.60 −1.20%
NeoGenomics, Inc. and Personalis, Inc. are both Diagnostics & Research companies. NeoGenomics, Inc. is the larger, with a market value of $2.1B against $1.7B — 1.3× the size. Personalis, Inc. grew revenue faster over the last twelve months: 16.9% against 11.1%. NeoGenomics, Inc. has the higher net margin (−4.10% vs −147.7%) and the higher return on invested capital (−2.97% vs −358.4%). Across the 18 metrics below, NeoGenomics, Inc. leads on 14 and Personalis, Inc. on 4.
Valuation
Profitability
| Metric | NEO | PSNL | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 44.77% | 16.71% | 48.32% |
| Operating margin | (6.27%) | (156.66%) | (5.68%) |
| Net margin | (4.10%) | (147.74%) | (4.10%) |
| Free cash flow margin | (3.37%) | (120.79%) | 0.00% |
| Return on equity | (3.94%) | (62.14%) | 0.00% |
| Return on assets | (2.35%) | (44.66%) | (6.05%) |
| Return on invested capital | (2.97%) | (358.37%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack